vs
碧迪（BDX）与皇家加勒比集团（RCL）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是皇家加勒比集团的1.2倍（$5.3B vs $4.3B），皇家加勒比集团净利率更高（17.7% vs 7.3%，领先10.4%），皇家加勒比集团同比增速更快（13.3% vs -0.4%），碧迪自由现金流更多（$549.0M vs $116.0M），过去两年皇家加勒比集团的营收复合增速更高（6.9% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
皇家加勒比集团前身为皇家加勒比邮轮有限公司，是仅次于嘉年华公司的全球第二大邮轮运营商。集团总部位于美国佛罗里达州迈阿密，在利比里亚注册，目前全资拥有皇家加勒比国际游轮、名人邮轮、银海邮轮三大品牌，还持有途易邮轮50%的股份。
BDX vs RCL — 直观对比
营收规模更大
BDX
是对方的1.2倍
$4.3B
营收增速更快
RCL
高出13.7%
-0.4%
净利率更高
RCL
高出10.4%
7.3%
自由现金流更多
BDX
多$433.0M
$116.0M
两年增速更快
RCL
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $4.3B |
| 净利润 | $382.0M | $753.0M |
| 毛利率 | 45.9% | 47.4% |
| 营业利润率 | 10.5% | 21.9% |
| 净利率 | 7.3% | 17.7% |
| 营收同比 | -0.4% | 13.3% |
| 净利润同比 | 24.0% | 36.4% |
| 每股收益（稀释后） | $1.34 | $2.76 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXRCL
| Q4 25 | $5.3B | $4.3B | ||
| Q3 25 | $5.9B | $5.1B | ||
| Q2 25 | $5.5B | $4.5B | ||
| Q1 25 | $5.3B | $4.0B | ||
| Q4 24 | $5.2B | $3.8B | ||
| Q3 24 | $5.4B | $4.9B | ||
| Q2 24 | $5.0B | $4.1B | ||
| Q1 24 | $5.0B | $3.7B |
净利润BDXRCL
| Q4 25 | $382.0M | $753.0M | ||
| Q3 25 | $493.0M | $1.6B | ||
| Q2 25 | $574.0M | $1.2B | ||
| Q1 25 | $308.0M | $730.0M | ||
| Q4 24 | $303.0M | $552.0M | ||
| Q3 24 | $400.0M | $1.1B | ||
| Q2 24 | $487.0M | $854.0M | ||
| Q1 24 | $537.0M | $360.0M |
毛利率BDXRCL
| Q4 25 | 45.9% | 47.4% | ||
| Q3 25 | 47.5% | 51.8% | ||
| Q2 25 | 47.8% | 49.7% | ||
| Q1 25 | 42.8% | 48.0% | ||
| Q4 24 | 43.2% | 45.4% | ||
| Q3 24 | 45.7% | 51.1% | ||
| Q2 24 | 46.2% | 47.6% | ||
| Q1 24 | 45.7% | 44.8% |
营业利润率BDXRCL
| Q4 25 | 10.5% | 21.9% | ||
| Q3 25 | 11.8% | 33.1% | ||
| Q2 25 | 16.0% | 29.3% | ||
| Q1 25 | 10.4% | 23.6% | ||
| Q4 24 | 8.8% | 16.6% | ||
| Q3 24 | 11.4% | 33.4% | ||
| Q2 24 | 12.1% | 26.7% | ||
| Q1 24 | 14.5% | 20.1% |
净利率BDXRCL
| Q4 25 | 7.3% | 17.7% | ||
| Q3 25 | 8.4% | 30.6% | ||
| Q2 25 | 10.4% | 26.7% | ||
| Q1 25 | 5.8% | 18.3% | ||
| Q4 24 | 5.9% | 14.7% | ||
| Q3 24 | 7.4% | 22.7% | ||
| Q2 24 | 9.8% | 20.8% | ||
| Q1 24 | 10.6% | 9.7% |
每股收益（稀释后）BDXRCL
| Q4 25 | $1.34 | $2.76 | ||
| Q3 25 | $1.71 | $5.74 | ||
| Q2 25 | $2.00 | $4.41 | ||
| Q1 25 | $1.07 | $2.70 | ||
| Q4 24 | $1.04 | $2.27 | ||
| Q3 24 | $1.37 | $4.21 | ||
| Q2 24 | $1.68 | $3.11 | ||
| Q1 24 | $1.85 | $1.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $825.0M |
| 总债务越低越好 | — | $18.2B |
| 股东权益账面价值 | $25.3B | $10.0B |
| 总资产 | $54.8B | $41.6B |
| 负债/权益比越低杠杆越低 | — | 1.81× |
8季度趋势，按日历期对齐
现金及短期投资BDXRCL
| Q4 25 | $740.0M | $825.0M | ||
| Q3 25 | $641.0M | $432.0M | ||
| Q2 25 | $735.0M | $735.0M | ||
| Q1 25 | $667.0M | $386.0M | ||
| Q4 24 | $711.0M | $388.0M | ||
| Q3 24 | $1.7B | $418.0M | ||
| Q2 24 | $4.5B | $391.0M | ||
| Q1 24 | $2.3B | $437.0M |
总债务BDXRCL
| Q4 25 | — | $18.2B | ||
| Q3 25 | — | $17.2B | ||
| Q2 25 | — | $17.6B | ||
| Q1 25 | — | $18.0B | ||
| Q4 24 | — | $18.5B | ||
| Q3 24 | — | $19.0B | ||
| Q2 24 | — | $19.8B | ||
| Q1 24 | — | $18.9B |
股东权益BDXRCL
| Q4 25 | $25.3B | $10.0B | ||
| Q3 25 | $25.4B | $10.1B | ||
| Q2 25 | $25.5B | $9.2B | ||
| Q1 25 | $25.2B | $8.0B | ||
| Q4 24 | $25.2B | $7.6B | ||
| Q3 24 | $25.9B | $7.0B | ||
| Q2 24 | $25.9B | $6.0B | ||
| Q1 24 | $25.6B | $5.2B |
总资产BDXRCL
| Q4 25 | $54.8B | $41.6B | ||
| Q3 25 | $55.3B | $40.1B | ||
| Q2 25 | $54.9B | $38.5B | ||
| Q1 25 | $54.5B | $37.5B | ||
| Q4 24 | $54.7B | $37.1B | ||
| Q3 24 | $57.3B | $37.1B | ||
| Q2 24 | $55.6B | $37.0B | ||
| Q1 24 | $54.2B | $35.2B |
负债/权益比BDXRCL
| Q4 25 | — | 1.81× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.26× | ||
| Q4 24 | — | 2.44× | ||
| Q3 24 | — | 2.69× | ||
| Q2 24 | — | 3.29× | ||
| Q1 24 | — | 3.66× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $1.6B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $116.0M |
| 自由现金流率自由现金流/营收 | 10.5% | 2.7% |
| 资本支出强度资本支出/营收 | 2.1% | 35.4% |
| 现金转化率经营现金流/净利润 | 1.72× | 2.16× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $1.2B |
8季度趋势，按日历期对齐
经营现金流BDXRCL
| Q4 25 | $657.0M | $1.6B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $164.0M | $1.6B | ||
| Q4 24 | $693.0M | $1.5B | ||
| Q3 24 | $1.2B | $897.0M | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $514.0M | $1.3B |
自由现金流BDXRCL
| Q4 25 | $549.0M | $116.0M | ||
| Q3 25 | $1.0B | $-989.0M | ||
| Q2 25 | $1.0B | $910.0M | ||
| Q1 25 | $35.0M | $1.2B | ||
| Q4 24 | $588.0M | $915.0M | ||
| Q3 24 | $882.0M | $563.0M | ||
| Q2 24 | $1.1B | $-567.0M | ||
| Q1 24 | $380.0M | $1.1B |
自由现金流率BDXRCL
| Q4 25 | 10.5% | 2.7% | ||
| Q3 25 | 17.0% | -19.2% | ||
| Q2 25 | 19.0% | 20.1% | ||
| Q1 25 | 0.7% | 30.0% | ||
| Q4 24 | 11.4% | 24.3% | ||
| Q3 24 | 16.2% | 11.5% | ||
| Q2 24 | 22.4% | -13.8% | ||
| Q1 24 | 7.5% | 29.1% |
资本支出强度BDXRCL
| Q4 25 | 2.1% | 35.4% | ||
| Q3 25 | 6.0% | 47.8% | ||
| Q2 25 | 3.2% | 18.4% | ||
| Q1 25 | 2.4% | 10.7% | ||
| Q4 24 | 2.0% | 14.7% | ||
| Q3 24 | 5.4% | 6.8% | ||
| Q2 24 | 3.6% | 52.1% | ||
| Q1 24 | 2.7% | 6.5% |
现金转化率BDXRCL
| Q4 25 | 1.72× | 2.16× | ||
| Q3 25 | 2.75× | 0.93× | ||
| Q2 25 | 2.12× | 1.44× | ||
| Q1 25 | 0.53× | 2.23× | ||
| Q4 24 | 2.29× | 2.66× | ||
| Q3 24 | 2.94× | 0.81× | ||
| Q2 24 | 2.66× | 1.84× | ||
| Q1 24 | 0.96× | 3.69× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
RCL
| Passenger | $2.9B | 69% |
| Other | $1.3B | 31% |
